TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26509152
Drug: Taper-shaped cuffs
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper-shaped cuffs
Study: 28271073
Drug: Sorafenib (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (first-line therapy)
Study: 26354521
Drug: mDCF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: mDCF (docetaxel 40 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1, 5FU 1000 mg/m2/d days 1 and 2, cisplatin 40 mg/m2 day 3)
Study: 26354521
Drug: EOX (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOX (epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, capecitabine 1250 mg/m2/d days 1-21)
Study: 26675778
Drug: Astaxanthin 12
Normalized name: astaxanthin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin 12 mg/d
Study: 11728846
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment
Study: 2647846
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of treatment
Study: 21808844
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg midazolam
Study: 1980464
Drug: Lormetazepam 2
Normalized name: lormetazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam 2 mg
Study: 2907315
Drug: Lorazepam 4
Normalized name: lorazepam 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 4 mg
Study: 26454186
Drug: Interpersonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal therapy (IPT) intervention, n=104
Study: 26454186
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) control, n=101
Study: 11062382
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg QD flutamide
Study: 11062382
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg q8h flutamide
Study: 16971821
Drug: PTSD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTSD treatment
Study: 21677124
Drug: HIGH (≥1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH (≥1200 mg calcium)
Study: 11252549
Drug: efavirenz-containing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz-containing triple therapy
Study: 11252549
Drug: indinavir-containing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: indinavir-containing triple therapy
Study: 9628275
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg once daily for 8 weeks
Study: 1957991
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Olea europaea extracts
Study: 21309444
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (control group)
Study: 14816
Drug: Atenolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (200 mg daily for five weeks)
Study: 17260365
Drug: Reviparin 3,436
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin 3,436 IU subcutaneously twice daily
Study: 9109726
Drug: buccal bioadhesive
Normalized name: urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: buccal bioadhesive slow‐release tablet containing miconazole nitrate
Study: 31340534
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of CurcuWIN® (50 mg of curcuminoids)
Study: 18462734
Drug: Unidirectional buccoadhesive
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unidirectional buccoadhesive bromocriptine methylate discs once daily for 1 month
Study: 18462734
Drug: Vaginoadhesive bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginoadhesive bromocriptine methylate discs once daily for 1 month
Study: 15365788
Drug: l-dopa
Normalized name: L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: l-dopa
Study: 11726036
Drug: Lactoferrin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin (20 mg daily for 5 days before surgery)
Study: 9396978
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (n = 13): encasing mattress, box springs, and pillows in allergen impermeable covers; weekly hot water wash of bed linens; replacement of bedroom carpet with polished flooring; and 3% tannic acid spray to living room carpet.
Study: 9396978
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n = 10): permeable encasing for bedding, cold water wash, and water spray for carpet.
Study: 31839530
Drug: Extended-release albuterol
Normalized name: albuterol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release albuterol
Study: 23613501
Drug: Tidal volumes
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volumes of 6, 8, or 10 ml/kg with initial FD of sevoflurane at 2.2% vol in study 2
Study: 15110928
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum leptin levels at discharge from inpatient treatment
Study: 11061603
Drug: BEACOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEACOPP chemotherapy (dose-intensified variant, arm 2)
Study: 11061603
Drug: BEACOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEACOPP chemotherapy (baseline variant, arm 1)
Study: 1390143
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic limb ulcer therapy (PELUT) device used at home for 3 hours daily for 8 weeks as an adjunct to a wound dressing
Study: 1390143
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic limb ulcer therapy (PELUT) device
Study: 3890197
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (recombinant DNA origin)
Study: 3890197
Drug: Iletin II
Normalized name: NPH Iletin II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iletin II pork insulin
Study: 24280948
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose laser (0.2 J/point)
Study: 22496161
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg/d)
Study: 20615494
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40 IU twice a day for 3 weeks)
Study: 17604300
Drug: Probiotic drink
Normalized name: CVS Probiotic Drink Mix 10 Billion CFU Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic drink containing Lactobacillus casei, L bulgaricus, and Streptococcus thermophilus.
Study: 15685041
Drug: Intracavitary hyperthermia
Normalized name: carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavitary hyperthermia (ICHT) combined with chemotherapy (5‐FU and mitomycin‐C) and radiotherapy.
Study: 15685041
Drug: Chemotherapy (5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5‐FU and mitomycin‐C) and radiotherapy without ICHT.
Study: 9503043
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with antioxidant vitamins (vitamin C, 120 mg; vitamin E, 30 mg; beta‐carotene, 6 mg) and minerals (selenium, 100 micrograms; zinc, 20 mg)
Study: 2691421
Drug: Analgesic nitrous
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analgesic nitrous oxide
Study: 24885267
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block (0.5 mls/kg 0.25% levo‐bupivacaine) followed by ropivacaine (0.2% 5 ml/hr‐1) infused via a femoral nerve catheter until 48 hours post‐surgery
Study: 9063856
Drug: Low-energy extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy extracorporeal shock wave therapy (ESWT)
Study: 12616982
Drug: Oral 17
Normalized name: polyoxypropylene (17)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17 beta-oestradiol daily for 6 weeks
Study: 27352623
Drug: NIAT-rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIAT-rituximab (375 mg/m2 intravenous rituximab on days 1 and 8)
Study: 7742263
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER (FER) 5 mg once daily, increased to 10 mg if necessary
Study: 35197
Drug: Clobazam (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (dosage ranged from 5 mg daily to 120 mg daily, usual daily dosage in out-patient therapy 20-30 mg)
Study: 35197
Drug: Clobazam (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (dosage ranged from 5 mg daily to 120 mg daily)
Study: 28608121
Drug: Neoadjuvant S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant S-1 with concurrent hypofractionated radiotherapy (30 Gy in 10 fractions, S-1 at 60 mg/m2, 5 days/week for 2 weeks)
Study: 25645170
Drug: Adjunctive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive intervention consisting of two sessions of psychoeducation and skills training in reducing accommodation.
Study: 27465573
Drug: 27‐gauge (G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27‐gauge (G) pars plana vitrectomy (PPV)
Study: 27465573
Drug: 25‐G pars
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐G pars plana vitrectomy (PPV)
Study: 9060195
Drug: 24-hour transdermal
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour transdermal nicotine patch
Study: 24341301
Drug: Vortioxetine 5
Normalized name: vortioxetine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 5 mg
Study: 12811500
Drug: Oxybutynin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin (5 mg twice daily)
Study: 8683844
Drug: GnRH‐agonist therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐agonist therapy after drainage of endometrioma for 6 months
Study: 8683844
Drug: GnRH‐agonist therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐agonist therapy alone for 6 months
Study: 27265353
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral co-trimoxazole prophylaxis (120 mg/day for <6 months, 240 mg/day for 6 months to 5 years)
Study: 27265353
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral co-trimoxazole prophylaxis
Study: 22285724
Drug: Atomoxetine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (mean final dose = 1.38 mg/kg)
Study: 16998214
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (mainly atorvastatin) in Group A
Study: 16998214
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin treatment in Group B
Study: 16998214
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment in Group C (without MetS)
Study: 16998214
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin treatment in Group D (without MetS)
Study: 15237767
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (800 mg/d)
Study: 2717287
Drug: Nonnutritive sucking
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonnutritive sucking (pacifier for 30 minutes with each feeding, 12 times per day until weight of 1,500 g, then 8 times per day)
Study: 1098832
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of folic acid after dialysis
Study: 1098832
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of folic acid after dialysis
Study: 23510124
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg once daily for 90 days
Study: 23510124
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 90 days
Study: 15587537
Drug: Dorsal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal block and ring block in combination with concentrated oral sucrose
Study: 15587537
Drug: Concentrated oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated oral sucrose alone
Study: 11717622
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of oral beta(2)-adrenergic receptor agonists (beta(2)-AG) for 2 weeks
Study: 11717622
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion with heart rate adjusted to 90 beats/min
Study: 9137794
Drug: Standard-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose cytarabine (SDAC)
Study: 22287757
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HDAC)
Study: 3595574
Drug: Pancuronium (cumulative-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (cumulative-dose method)
Study: 3595574
Drug: Tubocurarine (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine (single-dose method)
Study: 3595574
Drug: Tubocurarine (cumulative-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine (cumulative-dose method)
Study: 27473311
Drug: Mindfulness-Based Art
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Art Therapy (MBAT)
Study: 29122108
Drug: Non-insulin-treated T2DM
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin-treated T2DM
Study: 29122108
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (insulin initiators and non-initiators)
Study: 20371683
Drug: CHOP (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP (conventional chemotherapy)
Study: 16983932
Drug: Azelnidipine (8-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine (8-16 mg daily)
Study: 21929736
Drug: Amlodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5-10 mg daily)
Study: 8232485
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (250 mg every six hours for 3 days followed by oral prednisone (1 mg per kilogram of body weight) for 11 days)
Study: 8232485
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (1 mg per kilogram for 14 days)
Study: 8232485
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone compared to placebo
Study: 18788652
Drug: Nonpharmacological sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological sleep therapy for 6 weeks
Study: 16038599
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus fluoxetine combination therapy
Study: 22035648
Drug: Quetiapine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine monotherapy
Study: 10067800
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 to 10-20 mg once a day)
Study: 7669484
Drug: Ro 40‐5967
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 40‐5967 (50 mg daily)
Study: 7669484
Drug: Ro 40‐5967
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 40‐5967 (100 mg daily)
Study: 7669484
Drug: Digoxin alone
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin alone (0.375 mg daily)
Study: 7475716
Drug: Control (Meningococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Meningococcal vaccine)
Study: 26503021
Drug: Early AED
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early AED withdrawal starting 4 months after surgery, with intended complete cessation of drugs after 12 months.
Study: 21039927
Drug: Zilpaterol-HCl (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilpaterol-HCl (60 mg/day)
Study: 17545078
Drug: Intravenous hemocoagulase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hemocoagulase acutus at 2 U
Study: 11061989
Drug: 260 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 260 mg/d ascorbate plus 14 mg/d iron
Study: 24114551
Drug: Personalized text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized text messaging intervention (4-6 messages daily for 4 days)
Study: 10355212
Drug: Pain treatment
Normalized name: ARNICA MONTANA FLOWER 10 g in 50 g / SALIX ALBA BARK 15 g in 50 g / FRANKINCENSE 10 g in 50 g TOPICAL CREAM [HOUKEA Bone Pain Treatment Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain treatment
Study: 10355212
Drug: Analgesics 'as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics 'as needed'
Study: 8594426
Drug: Intravenous standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous standard heparin
Study: 8594426
Drug: Subcutaneous low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low-molecular-weight heparin
Study: 27456835
Drug: Microvascular disease
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microvascular disease (retinal photocoagulation therapy)
Study: 10585165
Drug: Acute creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute creatine loading (25 g per day for 4 days)
Study: 10585165
Drug: Longer-term creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer-term creatine supplementation (5 g of creatine per day for 2 months)
Study: 10585165
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 g per day for 2 months)
Study: 25669611
Drug: dezocine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: dezocine 0.1 mg/kg
Study: 24385131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of zolpidem
Study: 25734733
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of lorazepam
Study: 17709293
Drug: Visual analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual analogue scale for sedative effects
Study: 29122087
Drug: 8 mg/mL
Normalized name: valine 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/mL triamcinolone
Study: 29122087
Drug: 16 mg/mL
Normalized name: glycerin 16 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/mL triamcinolone
Study: 23161645
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral prednisone given daily for 10 days
Study: 18355422
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg alone
Study: 21810257
Drug: Sinvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinvastatin 40 mg plus ezetimibe 10 mg plus fiber (25 g)
Study: 21810257
Drug: Sinvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinvastatin 40 mg plus ezetimibe 10 mg
Study: 19369367
Drug: Lysine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine intake of 5 mg x kg(‐1) x d(‐1)
Study: 19369367
Drug: Lysine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine intake of 70 mg x kg(‐1) x d(‐1)
Study: 22975536
Drug: β‐blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐blockers
Study: 2882775
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel antagonists
Study: 11806300
Drug: Potassium channel
Normalized name: Potassium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium channel agonists
Study: 11806300
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of platelet aggregation
Study: 11806300
Drug: Antibiotics against
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics against intra‐cellular germs
Study: 9923567
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide (50 mg/m2 daily for 21 days)
Study: 7994805
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Streptokinase and TPA)
Study: 29437621
Drug: Murepavadin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Murepavadin (single ascending dose)
Study: 29437621
Drug: Murepavadin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Murepavadin (multiple ascending doses)
Study: 26377496
Drug: Usual transplant
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual transplant patient education plus ten additional weekly 30‐min education/counseling sessions about immunosuppressive drugs and behavioral changes
Study: 21792296
Drug: Intramuscular ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ACTH gel
Study: 21792296
Drug: Subcutaneous ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous ACTH gel
Study: 18055864
Drug: Decitabine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (100 mg/m² per course every 4 weeks)
Study: 10487558
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no xerostomy prevention therapy)
Study: 8533995
Drug: Mesalamine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 0.8 g/d
Study: 8533995
Drug: Mesalamine 1.6
Normalized name: Mesalamine 1.6 g gastro-resistant and prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 1.6 g/d
Study: 8533995
Drug: Mesalamine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 0.8 g/d (intention-to-treat)
Study: 8533995
Drug: Mesalamine 1.6
Normalized name: Mesalamine 1.6 g gastro-resistant and prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 1.6 g/d (intention-to-treat)